RecruitingNot ApplicableNCT06949579

Risk of Posterior Staphyloma in Highly Myopic Europeans : From Epidemiology to Anatomy.


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

200 participants

Start Date

Feb 2, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

In this cross-sectionnal study the aim is to increase the understanding of posterior staphyloma through a unique European consortium. Therefore, all eligible patients that either visit the outpatient clinic at Radboud in Nimegen, the Netherlands, or visit University Hopital Puerta de HierroMajadahonda in Madrid, Spain, or visit University Hospital Cochin in Paris, France, and after consenting, will be included. 600 high myopic European cases are expecting. A standardized protocol in all centers in order to create a uniform dataset. Besides the standard of care, blood samples will be collected. All data collected will be stored in an onlie Castor database


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called blood sampling for DNA for people with high myopia. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALblood sampling for DNA

Blood sampling for DNA and serum and plasma colection and PBMC


Locations(1)

Cochin Hospital

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06949579


Related Trials